Doctors are cleared to prescribe cheaper drug for wet AMDBMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k344 (Published 24 January 2018) Cite this as: BMJ 2018;360:k344
- Deborah Cohen
Doctors who prescribe bevacizumab (Avastin) for age related macular degeneration (AMD) will “not raise fitness to practise concerns,” the UK medical regulator has said, after the National Institute for Health and Care Excellence judged that the drug was as safe and effective as licensed treatments.
The General Medical Council’s chief executive, Charlie Massey, said, “Where doctors are working in partnership with patients, following clinical guidance, and making prescribing decisions in good faith on the basis of evidence and experience, the use of Avastin would not cause us any concerns.”
In its long awaited clinical guideline on AMD, NICE recommended that people with suspected late form of the disease (wet active) be referred to a macula service quickly for prompt diagnosis and fast access to effective treatments.1
For patients with confirmed late AMD, an antivascular endothelial growth factor (anti-VEGF) drug should be …